Paramesh Chetty
Overview
Explore the profile of Paramesh Chetty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Price M, Fast P, Mshai M, Lambrick M, Wangui Machira Y, Gieber L, et al.
PLOS Glob Public Health
. 2023 Mar;
2(11):e0000783.
PMID: 36962599
Region-specific laboratory reference intervals (RIs) are important for clinical trials and these data are often sparse in priority areas for research, including Africa. We reviewed data on RIs from Africa...
2.
Langat R, Farah B, Indangasi J, Ogola S, Omosa-Manyonyi G, Anzala O, et al.
Afr J Lab Med
. 2021 Apr;
10(1):1056.
PMID: 33833946
Background: Standardisation of procedures for performing cellular functional assays across laboratories participating in multicentre clinical trials is key for generating comparable and reliable data. Objective: This article describes the performance...
3.
Price M, Kilembe W, Ruzagira E, Karita E, Inambao M, Sanders E, et al.
Int J Epidemiol
. 2020 Sep;
50(1):29-30.
PMID: 32879950
No abstract available.
4.
Price M, Rida W, Kilembe W, Karita E, Inambao M, Ruzagira E, et al.
J Infect Dis
. 2019 Apr;
220(3):432-441.
PMID: 30938435
Few human immunodeficiency virus (HIV)-infected persons can maintain low viral levels without therapeutic intervention. We evaluate predictors of spontaneous control of the viral load (hereafter, "viral control") in a prospective...
5.
Karita E, Price M, Lakhi S, Kilembe W, Kamali A, Ruzagira E, et al.
PLoS One
. 2015 Aug;
10(8):e0134438.
PMID: 26291456
Background: 2013 WHO guidelines recommend starting ART at CD4+ T-cell counts ≤500 cells/μL. We present the T-cell counts from adult Africans with HIV shortly following transmission to their sexual partners....
6.
Kamali A, Price M, Lakhi S, Karita E, Inambao M, Sanders E, et al.
PLoS One
. 2015 Jan;
10(1):e0116100.
PMID: 25602351
HIV epidemiology informs prevention trial design and program planning. Nine clinical research centers (CRC) in sub-Saharan Africa conducted HIV observational epidemiology studies in populations at risk for HIV infection as...
7.
Schmidt C, Jaoko W, Omosa-Manyonyi G, Kaleebu P, Mpendo J, Nanvubya A, et al.
Hum Vaccin Immunother
. 2013 Dec;
10(3):714-23.
PMID: 24374365
Long-term safety is critical for the development and later use of a vaccine to prevent HIV/AIDS. Likewise, the persistence of vaccine-induced antibodies and their impact on HIV testing must be...
8.
Kibengo F, Ruzagira E, Katende D, Bwanika A, Bahemuka U, Haberer J, et al.
PLoS One
. 2013 Oct;
8(9):e74314.
PMID: 24086333
Background: Efficacy of oral pre-exposure prophylaxis (PrEP) in prevention of HIV acquisition has been evaluated using a daily regimen. However, adherence to long term daily medication is rarely perfect. Intermittent...
9.
Kilembe W, Keeling M, Karita E, Lakhi S, Chetty P, Price M, et al.
PLoS One
. 2012 Jun;
7(6):e37154.
PMID: 22715363
Background: Acute HIV infection (prior to antibody seroconversion) represents a high-risk window for HIV transmission. Development of a test to detect acute infection at the point-of-care is urgent. Methods: Volunteers...
10.
Mutua G, Sanders E, Mugo P, Anzala O, Haberer J, Bangsberg D, et al.
PLoS One
. 2012 Apr;
7(4):e33103.
PMID: 22511916
Background: Little is known about safety of and adherence to intermittent HIV PrEP regimens, which may be more feasible than daily dosing in some settings. We present safety and adherence...